AbbVie pays $20bn in cash and stock for Pharmacyclics
AbbVie Inc. is buying Pharmacyclics Inc. for $261.25 per share (a 31% premium) in cash (58%) and AbbVie equity (42%), valuing the transaction at $20bn.
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.